Drug intelligence / Profile preview

actinium Ac 225 lintuzumab + cemiplimab

Development stage: Unknown
Lead developer: Actinium Pharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Actimab-A + cemiplimab is an investigational combination therapy being evaluated for the treatment of recurrent IDH-wildtype glioblastoma. Actimab-A (actinium Ac 225 lintuzumab) is a radioimmunoconjugate consisting of a humanized monoclonal antibody targeting CD33 (lintuzumab) labeled with the alpha-emitting radioisotope actinium-225. It is designed to deliver high-energy alpha radiation directly to CD33-expressing cells, which are found on glioblastoma cells and within the tumor microenvironment. Cemiplimab is a fully human monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) receptor, a key immune checkpoint. By blocking the PD-1/PD-L1 pathway, cemiplimab aims to restore and enhance the body's anti-tumor T-cell response. This combination is currently being studied in a Phase I dose-escalation trial sponsored by the National Cancer Institute (NCI) to determine safety and preliminary efficacy in patients with recurrent glioblastoma.

Brand names: Libtayo
Other names: actinium Ac 225 lintuzumabcemiplimab225Ac-anti-CD33Actimab-A-National Cancer Institute (NCI)-glioblastoma

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on actinium Ac 225 lintuzumab + cemiplimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on actinium Ac 225 lintuzumab + cemiplimab.

Explore the full profile